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A B S T R A C T
Accumulating data from observational studies showed that online hemodiafiltration (OLHDF) might improve sur-
vival in chronic hemodialysis (HD) patients. According to this data, the aim of our study was to investigate whether there
was a difference in survival of patients treated with OLHDF compared to standard, conventional HD. We included 85
prevalent patients with end-stage renal disease (ESRD) treated with HD as a method of renal replacement therapy (RRT)
for more than three months. Patients were previously treated with HD and divided into two groups: in 42 patients new
treatment with OLHDF was introduced, and 43 patients were treated with HD. Both groups were followed over a period
of 36 months. The study showed significantly better survival of patients treated with OLHDF, compared to the survival of
patients treated with HD in the whole study population, as well as in the subgroups of diabetics, of patients who were on
RRT with HD for more than five years and of the patients who were older than 65 years. In the nondiabetics, patients
who were on RRT for less than five years and in the patients who were younger than 65 years, survival results in the
OLHDF group were not significantly better compared to those in the HD group. As in our study, there are accumulating
data from observational studies that HDF may improve survival in chronic HD patients, but new, prospective random-
ized trials are needed to support evidence about this hypothesis.
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Introduction
Significant increase in the incidence and prevalence
of chronic kidney disease (CKD) has been observed
worldwide. Epidemiological studies that include most in-
dustrialized countries and some developing countries
have shown that approximately every tenth adult in the
world or about 10% of the population in the developed
countries has CKD.
Therefore, today, worldwide more than one million
patients are treated with hemodialysis (HD) as a method
of choice of renal replacement therapy (RRT) in the end
stage renal disease (ESRD). Due to the rapid develop-
ment of dialysis technology over the last four decades,
RRT with dialysis has become a routine procedure, al-
though, morbidity and mortality in patients treated with
dialysis are still very high1,2. Cardiovascular diseases are
the leading cause of morbidity and mortality of patients
with ESRD, to a greater extent than in the general popu-
lation. In fact, about 50% of deaths in these patients are
related to cardiovascular causes3,4. ESRD patients are ex-
posed to numerous cardiovascular risk factors5. Some of
these factors are related to the primary disease that led
to the failure of renal function, and to associated diseases
and conditions, and some to undesirable effects and com-
plications of dialysis procedure6. Cardiovascular risk fac-
tors that patients in ESRD are exposed to, can be divided
into two groups. These are »traditional« general risk fac-
tors, such as older age, male gender, diabetes, hyperten-
sion, dyslipidemia, and »nontraditional,« »uremic«, car-
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diovascular risk factors, whose importance is growing
with renal function deterioration7. Important »uremic«
cardiovascular risk factors are malnutrition, inflamma-
tion, atherosclerosis, anemia, increased extracellular vol-
ume, thrombogenic factors, low delivered dose of dialy-
sis, type of dialysis membrane, type of dialysis procedure,
hyperphosphatemia, amyloidosis due to deposition of b2-
-microglobulin, etc.8–18. Association of separate cardio-
vascular risk factors increases the incidence of cardiovas-
cular disease significantly. Inflammation and oxidative
stress that patients receiving hemodialysis treatment are
exposed to, to a significant extent, are of particular
importance19–21. Inflammation and oxidative stress lead
to endothelial dysfunction and accelerated development
of atherosclerosis. One way to reduce hemodialysis-in-
duced inflammation and oxidative stress is the use of
OLHDF. In contrast to diffusive dialysis transport, which
mainly remove toxins of small molecular weight, in he-
modiafiltration, diffusive and convective transport are
combined, providing an optimal removal of both, small
and large, uremic toxic molecules. Clinical studies have
suggested that use of this method leads to reduction of
cardiovascular morbidity and mortality in these patients.
According to these observations, the aim of our study
was to evaluate whether there is a difference in survival
of patients treated with OLHDF compared to survival of
patients treated with standard, conventional HD and to
which extent.
Patients and Methods
The study included 85 patients on chronic program of
RRT. The follow-up period was 36 months. Three dialysis
centers have agreed to provide the required number of
patients. All patients were older than 18 years, and
signed the informed consent approved by the local Ethics
committee. The study was conducted in keeping with
good clinical practice guidelines. The patients with
ESRD were on regular HD for at least three months. Of
the 85 patients studied, 43 were treated with low-flux
HD but in 42 patients new treatment with OLHDF was
introduced, when became available, randomly. The fol-
low-up in the both patients groups was 36 months. The
intended HD treatment duration for both modality arms
of the trial was 240 min with a blood flow rate between
250 and 400 mL/min, as registered in a single hamodia-
lysis treatments. Patients with a blood flow lower than
250 mL/min, registered in the more than 30% treatments
3 months before enrollment were not included in the
study. Most patients has an AV fistula as a vascular ac-
cess (88% in OLHDF group and 86% in HD group, re-
spectively) and other patients has a catheter (12% vs
14%, respectively). The dialysate flow rate was kept at
500mL/min in both groups. The same high-flux dialyser
(Polysulfone-based Helixone Membrane, Fresenius Med-
ical Care, Bad Homburg, Germany) was used during the
entire study period. Dialysate composition was the same
in >90% of subjects in both arms of the study (Na 138
mmol/L, K 2.0 mmol/L, Ca 1.25 mmol/L, Mg 0.5 mmol/L,
Cl 109 mmol/L, HCO3 32 mmol/L, acetate 3 mmol/L, glu-
cose 5.5 mmol/L). Sodium modelling was not applied.
Low molecular weight heparin was used for anticoagula-
tion. Dialyser reuse was not permitted. Standard dialysa-
te was utilized in the HD group. OL-HDF procedure was
performed in the postdilution mode under strict safety
operational procedures. Fresenius 5008S dialysis ma-
chines, incorporating the ONLINEplus (Fresenius Medi-
cal Care, Bad Homburg, Germany) system were used.
This system consists of two ultrafilters (DIASAFEplus);
the first one is placed after the proportioning system and
the second is positioned before the substitution port.
Ultrafilters in-stalled on the haemodiafiltration (HDF)
machine were replaced after 100 treatments or 12 weeks
of use, whichever came first. Dialysate in the HD group
and infusate in the OL-HDF group were regularly as-
sessed for colony-forming units and endotoxin levels be-
fore change of ultrafilters. In the OL-HDF mode, the fil-
tration rates were adjusted to be between 25 and 30% of
the achieved blood flow rate and substitution volume was
targeted to be above 19 L per session. The electrolyte
composition of the infusate was the same as the composi-
tion of the dialysis fluid. During the study period, we an-
alyzed the overall survival of patients treated with
OLHDF compared to survival of patients treated with
conventional HD. Also, we compared survival of patients
divided into subgroups with respect to four important
criteria, such as age, vintage of RRT with HD, presence
of diabetes and whether they were or they were not on
kidney waiting list for transplantation.
Statistics
Statistical analysis of data was performed using des-
criptive statistics (mean and standard deviation). Cate-
gorical variables were tested by Fisher Exact test. Tes-
ting the importance of the difference of two independent
groups was performed using t-test. The difference in sur-
vival of patients was analyzed with Kaplan-Meyers’s
method of mortality risk. P-value <0.05 was considered
to be statistically significant. Statistical analysis was
made using licensed MedCalc statistical software pack-
age, version 11.5 (MedCalc, Mariakerke, Belgium).
Results
Out of 85 patients, there were 24 male (57.1%) and 18
female (42.9%) in the OLHDF group, and 26 male (60.5%)
and 17 female (39.5%) in the HD group. There were no
statistically significant difference between the two groups
related to gender, hemodialysis treatment parameters,
hemoglobin level, erythropoiesis stimulating agents use,
blood pressure and concomitant medication use (Table
1). The average age of patients was 58.45±11.04 years in
the OLHDF group, and 62.02±12.32 years in the HD
group. There was no statistically significant difference in
age between the groups (p=0.1634).
Furthermore, there was no statistically significant
difference in the vintage of dialysis treatment between
the two groups. The average time of RRT with hemo-
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dialysis was 99.69 ± 105.78 months in the OLHDF
group, and 84.90 ±78.31 months in the HD group (p=
0.4654).
In both groups of patients, primary renal disease was
chronic glomerulonephritis (in 35.7% of patients in the
OLHDF group and 30.2% in the HD group). Diabetic
nephropathy followed in frequency in both groups
(11.9% in OLHDF and 11.6% in HD group). In one of the
patients in OLHDF group and in four in the HD group
primary renal disease was unknown (Table 2).
In Kaplan-Mayer survival analysis patients in the
OLHDF group had significantly better survival com-
pared to those in the HD group (p=0.0172). Specifically,
in the OLHDF group five patients died, while in the
group of patients treated with HD there were 14 deaths
(Figure 1).
When patients were divided in subgroups according to
four important criteria, such as duration of dialysis, age,
status on the waiting list for kidney transplantation and
presence or absence of diabetes, significantly better sur-
vival of patients treated with OLHDF in the diabetic
group (p=0.0449) was obtained, as well as in the group of
patients who were not on the waiting list for kidney
transplantation (p=0.0311), in the group of patients who
were treated with hemodialysis for more than five years
(p=0.0097) and in the group of patients older than 65
years (p=0.0200). In the nondiabetic group, in patients
who were treated with dialysis for less than five years
and in patients younger than 65 years, we have found
better survival in the OLHDF group but the difference
was not statistically significant.
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Fig. 1. Kaplan-Meyer plot of survival curves in the OLHDF
group and in the HD group (P=0.0172)
TABLE 1
DEMOGRAPHIC AND HEMODIALYSIS TREATMENT CHARACTERISTICS OF THE PATIENTS
HD Group OLHDF Group p
Gender Male N (%) 26 (60.5) 24 (57.1) 0.8875
Female N (%) 17 (39.5) 18 (42.9) 1.0000
Age (years) 62.02±12.32 58.45±11.04 0.1634
Time on RRT (months) 84.90±78.31 99.69±105.78 0.4654
Interdialytic weight gain (L) 2.3±1.2 2.6±1.5 0.311
Systolic blood pressure (mmHg) 143±15 138±16 0.141
Diastolic blood pressure (mmHg) 85±12 88±15 0.311
Antihypertensive medication N (%) 34 (71) 31 (74) 0.376
Antihypertensive medication (average number of drugs) 2.3±0.9 2.1±0.6 0.233
Hemoglobin level (g/L) 107±15 109±21 0.614
ESA treatment N (%) 35 (81%) 36 (86) 0.404
Phosphate binders N (%) 26 (60) 24 (57) 0.464
Vitamin D or analog N (%) 14 (33) 12 (29) 0.435





Glomerular disease 15 35.7% 13 30.2%
Diabetic nephropathy 5 11.9% 5 11.6%
Nephrosclerosis 3 7.1% 4 9.3%
Pyelonephritis 2 4.8% 5 11.6%
Polycystic kidney disease 3 7.1% 1 2.3%
Other 13 31.0% 11 25.6%
Unkown 1 2.4% 4 9.3%
Total 42 100.0% 43 100.0%
In patients on the waiting list for kidney transplanta-
tion survival rates were better in the group treated with
standard, conventional HD, but the difference was not
statistically significant (p=0.3417). Overall survival ra-
tes and survival rates of patients by subgroups are shown
in Table 3.
Discussion
The aim of our study was to investigate whether
OLHFD had favorable effect on the outcome of patients
compared to conventional low-flux HD. We presented fa-
vorable effect of OLHDF in reducing the overall risk of
mortality in the whole study population, as well as in cer-
tain subgroups of patients, such as diabetics, patients
older than 65 years, patients who were on chronic RRT
program for more than five years and HD patients who
were not on the waiting list for kidney transplantation.
Thus, we have shown the beneficial effects of OLHDF in
the study population as a whole and in vulnerable groups
of patients.
Two large controlled, randomized studies (HEMO
and MPO) failed to demonstrate a beneficial effect of
high-flux membranes on overall survival outcomes. They
examined the effect of high-flux membranes compared to
low-flux, but not the impact of convective methods (HDF
and HF) compared to standard low-flux hemodialysis22.
HEMO study is a large, multi-center, randomized con-
trolled trial conducted in the U.S., which included 1846
prevalent patients who were on chronic RRT program
with HD for more than three months17,23. Patients who
were on chronic HD program for less than three months
were excluded from the study, as well as those whose to-
tal level of serum albumin was less than 2.6 g/dL, and pa-
tients with very large body weight, if it was not possible
to achieve the target Kt/V index of 1.3. Primary analyses
showed no statistically significant differences in survival
of patients on high-flux compared to low-flux membra-
nes, while secondary analyses showed a statistically sig-
nificant beneficial effect of high-flux membranes on the
outcome of patients who were on HD for more than 3.7
years.
MPO is also a large multi-center, controlled, random-
ized study conducted in Europe, which included 738 HD
incident patients24. It also failed to prove beneficial ef-
fects of high-flux membranes on overall survival out-
comes, but in the group of patients with serum albumin
below 4 g/dl, the results were significantly better in pa-
tients on high-flux membranes, as well as in patients
with diabetes in secondary analysis.
In a retrospective study, Vilar and colleagues com-
pared the effects of high-flux HD and OLHDF on clinical
outcomes, including patient survival25. The study in-
cluded 858 patients who were dialyzed in their center
over a period of 18 years. Patients were divided into two
groups depending on whether they were predominantly
treated with high-flux HD or HDF. Survival rates were
statistically significantly better in the predominantly
HDF group.
Cannaud and colleagues conducted the study as part
of the DOPPS study (Dialysis Outcomes and Practice
Patterns Study). This prospective, longitudinal, observa-
tional study included 2165 patients from five European
countries. Results showed 35% lower risk of mortality in
the group of patients treated with high-efficiency HDF
compared to patients treated with low- flux HD26.
The results of this study are confirmed by Jirka and
his associates, also in an observational, multi-center stu-
dy, which included 2546 patients from 56 centers in four
major European countries27. They showed a 42.7% re-
duction of mortality risk in the group of patients treated
with HDF compared to patients treated with low-flux
HD. After adjusting for age, sex, comorbidities and time
of RRT, the difference remained statistically significant
(35.3%).
RISCAVID study is another observational study that
showed a favorable effect of HDF on reducing mortality
risk. It is a prospective study that included 757 patients
who were monitored over a period of 30 months28. The
results showed a favorable effect of HDF on patients’
survival compared to low-flux hemodialysis.
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TABLE 3





























HD HDF HD HDF HD HDF HD HDF HD HDF HD HDF HD HDF HD HDF HD HDF
Number of
patients
43 42 20 22 23 20 21 10 22 32 7 16 36 26 5 5 38 37
Number of le-
thal outcome
14 5 5 4 9 1 9 0 5 5 0 2 14 4 3 1 11 4
P 0.0172* 0.4752 0.0097** 0.0200* 0.5057 0.3417 0.0311* 0.0449* 0.1492
* P<0.05, ** P<0.01, RRT – renal replacement therapy, OLHDF – online hemodiafiltration, HD – conventional hemodialysis
CONTRAST study (The Dutch Convective Transport
Study) is a multi-center, randomized, controlled study
that included 772 patients29. The aim of this study was to
investigate the effect of treatment modalities (OLHDF
and low-flux HD) on overall mortality from any cause,
and the morbidity and mortality due to cardiovascular
causes. The results failed to demonstrate a significant
difference in the survival of patients on OLHDF com-
pared to those on low-flux HD, but subgroup analyses
showed significantly better survival in patients on
OLHDF who have reached substitution volumes greater
than 20 liters per treatment. Main limitation of our
study is a small number of patients, but still identifies
vulnerable subgroups of patients, potentially with the
highest mortality, especially cardiovascular. Therefore,
our findings can be very useful for further investigations.
Conclusion
Although these studies, including our own, show the
beneficial effect of hemodiafiltration on improving clini-
cal outcomes and survival in chronic HD patients, there
is a need for stronger evidence from a large randomized
controlled trials to confirm this hypothesis.
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PRE@IVLJENJE BOLESNIKA LIJE^ENIH METODOM »ONLINE« HEMODIJAFILTRACIJE
U USPOREDBI S KONVENCIONALNOM HEMODIJALIZOM
S A @ E T A K
Dostupni podaci iz opservacijskih studija pokazuju da primjena »online« hemodijafiltracije (OLHDF) mo`e pobolj-
{ati pre`ivljavanje bolesnika lije~enih kroni~nom hemodijalizom (HD). Sukladno tome, cilj na{eg istra`ivanja bio je
ispitati postoji li razlika u pre`ivljavanju pacijenata lije~enih OLHDF odnosu na standardnu, konvencionalnu HD. U
istra`ivanje je uklju~eno 85 bolesnika u 5. stadiju kroni~ne bubre`ne bolesti (KBB) koji su lije~eni HD kao metodom
nadomje{tanja bubre`ne funkcije (NBF) tijekom vi{e od tri mjeseca. Svi pacijenti su prethodno lije~eni sa HD te su
podijeljeni u dvije skupine: u 42 bolesnika primijenjen je novi postupak (OLHDF), dok je preostalih 43 pacijenta i dalje
lije~eno konvencionalnom HD. Obje skupine su pra}ene tijekom 36 mjeseci. Rezultati su pokazali zna~ajno bolje pre-
`ivljavanje pacijenata lije~enih sa OLHDF, u odnosu na pacijente lije~ene sa HD u cijeloj promatranoj populaciji, kao i u
podgrupama dijabeti~ara, pacijenata koji su bili na NBF dulje od pet godina i u pacijenata koji su bili stariji od 65
godina. U nedijabeti~ara, pacijenata koji su bili na NBF manje od pet godina te u bolesnika koji su bili mla|i od 65
godina, nije zabilje`eno bolje pre`ivljavanje u OLHDF grupi u odnosu na pacijente u HD grupi. Kao {to je prikazano u
ovom istra`ivanju, postoje podaci iz opservacijskih studija da HDF mo`e pobolj{ati pre`ivljavanje u bolesnika na kroni-
~noj hemodijalizi, posebno u nekim podrgupama pacijenata, ali su potrebna prospektivna istra`ivanja, na ve}em broju
bolesnika za potvrdu te hipoteze.
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